Kyverna Therapeutics Inc (KYTX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$5.39-5.93%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Kyverna Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.784
Annual ending 2026-12-31
Revenue	—	12.5M
EPS	—	-2.761
Annual ending 2027-12-31
Revenue	—	17.2M
EPS	—	-3.116

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain cash runway into 2028	Kyverna Therapeutics aims to maintain a cash runway into 2028.	Intact	Cash runway falls short of 2028	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Management has stated the priority of maintaining a cash runway into 2028 in 3 quarters including 2025-Q4, 2026-Q1, and 2026-Q2. Cash and equivalents declined from $279.3 million at 2025-Q4 to $199.4 million at 2026-Q2, consistent with ongoing operations and development spending. The company reiterates the runway into 2028, indicating the trajectory is aligned with expectations but cash is being consumed as planned. Delivery assessment Oct 24, 2026
EPS trend toward less negative losses	A supporting condition in Kyverna Therapeutics Inc's published investment case. The stated target is EPS loss narrows from -2.88 in 2026 to better levels.	Broken	EPS loss worsens beyond -2.95 in 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Fund SPS BLA filing and Phase 3 gMG trial	It plans to fund its SPS BLA filing and Phase 3 gMG trial.	Intact	Failure to fund SPS BLA filing and Phase 3 gMG trial	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-3.12

$-2.94 → $-3.12 · observed estimates

FY2027 revenue$0.02B

Unavailable → $0.02B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-2.94	Unavailable	5 / 4
2026-07-25	$-2.94	Unavailable	5 / 4
2026-07-26	$-2.94	Unavailable	5 / 4
2026-07-27	$-2.94	Unavailable	5 / 4
2026-07-28	$-2.95	$17,596,720	5 / 5
2026-07-29	$-2.95	$17,596,720	5 / 5
2026-07-30	$-2.95	$17,596,720	5 / 5
2026-07-31	$-2.94	Unavailable	5 / 4
2026-08-01	$-2.94	Unavailable	5 / 4
2026-08-02	$-2.95	$17,596,720	5 / 5
2026-08-03	$-2.95	$17,596,720	5 / 5
2026-08-04	$-2.95	$17,596,720	5 / 5
2026-08-05	$-2.95	$17,596,720	5 / 5
2026-08-06	$-2.94	Unavailable	5 / 4
2026-08-07	$-2.94	Unavailable	5 / 4
2026-08-08	$-2.95	$17,596,720	5 / 5
2026-08-09	$-2.94	Unavailable	5 / 4
2026-08-10	$-2.95	$17,596,720	5 / 5
2026-08-12	$-2.95	$17,596,720	5 / 5
2026-08-13	$-2.94	Unavailable	5 / 4
2026-08-14	$-2.94	Unavailable	5 / 4
2026-08-15	$-2.94	Unavailable	5 / 4
2026-08-16	$-2.94	Unavailable	5 / 4
2026-08-17	$-2.94	Unavailable	5 / 4
2026-08-18	$-2.94	Unavailable	5 / 4
2026-08-19	$-2.94	Unavailable	5 / 4
2026-08-20	$-3.03	Unavailable	5 / 4
2026-08-21	$-3.03	Unavailable	5 / 4
2026-08-22	$-3.03	Unavailable	5 / 4
2026-08-23	$-3.03	Unavailable	5 / 4
2026-08-24	$-3.03	Unavailable	5 / 4
2026-08-25	$-3.03	Unavailable	5 / 4
2026-08-26	$-3.03	Unavailable	5 / 4
2026-08-27	$-3.03	Unavailable	5 / 4
2026-08-28	$-3.03	Unavailable	5 / 4
2026-08-29	$-3.03	Unavailable	5 / 4
2026-08-30	$-3.03	Unavailable	5 / 4
2026-08-31	$-3.03	Unavailable	5 / 4
2026-09-01	$-3.03	Unavailable	5 / 4
2026-09-02	$-3.03	Unavailable	5 / 4
2026-09-03	$-3.03	Unavailable	5 / 4
2026-09-04	$-3.03	Unavailable	5 / 4
2026-09-05	$-3.03	Unavailable	5 / 4
2026-09-06	$-3.03	Unavailable	5 / 4
2026-09-07	$-3.03	Unavailable	5 / 4
2026-09-08	$-3.03	Unavailable	5 / 4
2026-09-09	$-3.03	Unavailable	5 / 4
2026-09-10	$-3.03	Unavailable	5 / 4
2026-09-11	$-3.03	Unavailable	5 / 4
2026-09-12	$-3.03	Unavailable	5 / 4
2026-09-13	$-3.03	Unavailable	5 / 4
2026-09-14	$-3.03	Unavailable	5 / 4
2026-09-15	$-3.03	Unavailable	5 / 4
2026-09-16	$-3.03	Unavailable	5 / 4
2026-09-17	$-3.03	Unavailable	5 / 4
2026-09-18	$-3.03	Unavailable	5 / 4
2026-09-19	$-3.03	Unavailable	5 / 4
2026-09-20	$-3.03	Unavailable	5 / 4
2026-09-21	$-3.03	Unavailable	5 / 4
2026-09-22	$-3.03	Unavailable	5 / 4
2026-09-23	$-3.03	Unavailable	5 / 4
2026-09-24	$-3.03	Unavailable	5 / 4
2026-09-25	$-3.03	Unavailable	5 / 4
2026-09-26	$-3.12	$17,196,460	5 / 5
2026-09-27	Unavailable	$17,196,460	4 / 5
2026-09-28	$-3.12	$17,196,460	5 / 5
2026-09-29	$-3.12	$17,196,460	5 / 5
2026-09-30	$-3.12	$17,196,460	5 / 5
2026-10-01	$-3.12	$17,196,460	5 / 5
2026-10-02	$-3.12	$17,196,460	5 / 5
2026-10-03	$-3.12	$17,196,460	5 / 5
2026-10-04	$-3.12	$17,196,460	5 / 5
2026-10-05	$-3.12	$17,196,460	5 / 5
2026-10-06	$-3.12	$17,196,460	5 / 5
2026-10-07	$-3.12	$17,196,460	5 / 5
2026-10-08	$-3.12	$17,196,460	5 / 5
2026-10-09	$-3.12	$17,196,460	5 / 5
2026-10-10	$-3.12	$17,196,460	5 / 5
2026-10-11	$-3.12	$17,196,460	5 / 5
2026-10-12	$-3.12	$17,196,460	5 / 5
2026-10-13	$-3.12	$17,196,460	5 / 5
2026-10-14	$-3.12	$17,196,460	5 / 5
2026-10-15	$-3.12	$17,196,460	5 / 5
2026-10-16	$-3.12	$17,196,460	5 / 5
2026-10-17	$-3.12	$17,196,460	5 / 5
2026-10-18	$-3.12	$17,196,460	5 / 5
2026-10-19	$-3.12	$17,196,460	5 / 5
2026-10-20	$-3.12	$17,196,460	5 / 5
2026-10-21	$-3.12	$17,196,460	5 / 5
2026-10-22	$-3.12	$17,196,460	5 / 5
2026-10-23	$-3.12	$17,196,460	5 / 5
2026-10-24	$-3.12	$17,196,460	5 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	6	0	0
2026-06-01	6	0	0
2026-07-01	6	0	0
2026-08-01	6	0	0
2026-09-01	6	0	0
2026-10-01	6	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

NeedhamSep 25

$25.00New observation · no comparable prior

$0$13.75$27.50

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain cash runway into 2028Direct metric needs a verified mapping
EPS trend toward less negative lossesPublished status: Broken
Fund SPS BLA filing and Phase 3 gMG trialDirect metric needs a verified mapping

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.7%Typical daily move · historical

Downside history

-52.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Kyverna Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotech story, not an established earnings compounder. The long-term thesis is in a watch state: progress toward the miv-cel submission is on track, but confidence is low and the company remains loss-making.

What's priced into Kyverna Therapeutics Inc

The evidence snapshot provides no valuation or market-expectations data, so whether KYTX is cheap or expensive versus peers cannot be assessed. It does show a recent downward price reaction and performance below its industry cohort, but does not establish what the market already assumes about miv-cel or a potential launch.

What the fundamentals likely do

Near term, KYTX is likely to remain loss-making as it funds development and launch preparation; cash fell from $279.3 million at 2025-Q4 to $199.4 million at 2026-Q2, while management continues to state a runway into 2028. Management is on track to complete the rolling BLA submission for miv-cel in SPS by Q4 2026 and is preparing for a potential 2027 launch, but manufacturing capacity details remain limited. Near-term reporting risk is elevated, with a 42% miss probability in the snapshot and guidance cuts flagged as a negative scenario.

What Kyverna Therapeutics Inc hinges on

The multi-year view hinges on completing the submission on schedule, progressing toward FDA approval, and preparing a viable commercial launch. It also depends on cash lasting into 2028 and scalable manufacturing being secured; the evidence shows progress, but the manufacturing outlook is not quantified. In the near term, guidance, economic data, and broader Healthcare sector results are the main listed swing factors.